Candel Therapeutics (CADL) Net Cash Flow (2020 - 2025)
Candel Therapeutics (CADL) posted Net Cash Flow of $32.9 million for Q4 2025, up 339.86% sequentially from -$13.7 million in Q3 2025, and down 61.77% YoY from $86.1 million in Q4 2024.
Candel Therapeutics (CADL) Net Cash Flow (2020 - 2025) Analysis & Trends
Candel Therapeutics has reported Net Cash Flow for 6 years, with the latest figure at $32.9 million in Q4 2025.
- Quarterly Net Cash Flow fell 61.77% year-over-year to $32.9 million in Q4 2025, while the trailing twelve-month figure through Dec 2025 was $17.2 million (down 74.38% YoY) and the FY2025 annual result came in at $17.2 million, down 74.38% from the prior year.
- Net Cash Flow advanced to $32.9 million in Q4 2025 per CADL's latest filing, from -$13.7 million in the prior quarter.
- Over five years, Net Cash Flow peaked at $86.1 million in Q4 2024 and troughed at -$13.7 million in Q3 2025.
- A 5-year average of $4.2 million and a median of -$6.4 million in 2021 frame the typical range for Net Cash Flow.
- The sharpest annual moves came in 2021 and 2023: Net Cash Flow jumped 2964.06% in 2021, then sank 192.37% in 2023.
- Over 5 years, Net Cash Flow stood at -$5.7 million in 2021, then retreated by 24.09% to -$7.1 million in 2022, then dropped by 6.25% to -$7.6 million in 2023, then surged by 1237.33% to $86.1 million in 2024, then slumped by 61.77% to $32.9 million in 2025.
- According to Business Quant data, Net Cash Flow over the past three periods registered $32.9 million, -$13.7 million, and $8.5 million for Q4 2025, Q3 2025, and Q2 2025 respectively.
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Net Cash Flow (Qtr) |
|---|---|---|---|---|---|
| 1 | Vertex Pharmaceuticals | 128.13 Bn | 120.28 Bn | 2.84 Bn | 652.90 Mn |
| 2 | Regeneron Pharmaceuticals | 112.33 Bn | 104.33 Bn | 3.93 Bn | -504.30 Mn |
| 3 | Argenx Se | 53.24 Bn | 48.05 Bn | 1.41 Bn | - |
| 4 | Revolution Medicines | 43.64 Bn | 43.64 Bn | - | 374.50 Mn |
| 5 | BeOne Medicines | 39.27 Bn | 34.17 Bn | 1.53 Bn | 407.41 Mn |
| 6 | MindWalk Holdings | 35.32 Bn | 35.31 Bn | 1.82 Bn | 17.81 Mn |
| 7 | Royalty Pharma | 33.72 Bn | 35.84 Bn | - | 225.59 Mn |
| 8 | Alnylam Pharmaceuticals | 30.58 Bn | 27.27 Bn | 992.69 Mn | -496,000.00 |
| 9 | Insmed | 27.01 Bn | 25.85 Bn | 358.27 Mn | -37.14 Mn |
| 10 | Candel Therapeutics | 643.41 Mn | 643.41 Mn | - | 32.92 Mn |
Historic Data
Download Data| Date | Value |
|---|---|
| Dec 31, 2025 | 32.92 Mn |
| Dec 31, 2025 | 32.92 Mn |
| Sep 30, 2025 | -13.72 Mn |
| Sep 30, 2025 | -13.72 Mn |
| Jun 30, 2025 | 8.52 Mn |
| Jun 30, 2025 | 8.52 Mn |
| Mar 31, 2025 | -10.49 Mn |
| Mar 31, 2025 | -10.49 Mn |
| Dec 31, 2024 | 86.10 Mn |
| Dec 31, 2024 | 86.10 Mn |
| Sep 30, 2024 | -4.90 Mn |
| Sep 30, 2024 | -4.90 Mn |
| Jun 30, 2024 | -4.26 Mn |
| Jun 30, 2024 | -4.26 Mn |
| Mar 31, 2024 | -9.70 Mn |
| Mar 31, 2024 | -9.70 Mn |
| Dec 31, 2023 | -7.57 Mn |
| Dec 31, 2023 | -7.57 Mn |
| Sep 30, 2023 | -8.91 Mn |
| Sep 30, 2023 | -8.91 Mn |